Fundraising FoxNectero Medical
Dover, US · Founded 2017 · 6 known investors
Find your way into Nectero Medical
Sign up to see every warm intro you have to Nectero Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nectero Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.
Founders & leadership
JS
Jack SpringerChief Executive OfficerHe serves as executive chairman of R3 Vascular and managing director at RM Global Partners, and previously held the same chairman role at Capture Vascular and served as a board member and consultant to Vatrix Medical. Earlier in his career he was vice president of commercial operations and brand marketing at Medtronic and president of US operations at INVATEC, and he has run JDS Consulting, a medical devices and diagnostics practice.
Investors · 6
Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M
How we know: av.vc · Not right? Tell us
Corewell Health Ventureslisted by Corewell Health VenturesGrand Rapids
How we know: Corewell Health Ventures's portfolio page · Not right? Tell us
BioStar CapitalreportedCharlevoix · $250K – $3M
How we know: funding news · Not right? Tell us
Norwest Venture PartnersreportedMenlo Park · $10M – $30M
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Boston Scientific Corporationlead
Reported raises · per SEC filings
Form D private placements$51M disclosed across 2 of 3 rounds · 2020–2024
▶$32.8MraisedMay 2024 · 30 investors · BiotechnologyRule 506(b)
▶$32.8MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anil DasuDirector
- Colin MorrisonDirector
- Bryan ZieglerExecutive Officer
- Bruce RobertsDirector
- Jack SpringerExecutive Officer, Director
- Robert WhirleyDirector
- Offering amount
- $96.6M
- Amount sold
- $32.8M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedSep 2021 · 31 investors · BiotechnologyRule 506(b)
▶$18.2MraisedSep 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Offering amount
- $18.2M
- Amount sold
- $18.2M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MofferedApr 2020 · BiotechnologyRule 506(b)
▶$1.5MofferedApr 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SpringerExecutive Officer, Director
- Bruce RobertsDirector
- Offering amount
- $1.5M
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nectero Medical do?
- Nectero Therapeutics develops therapeutic devices for vascular medicine, working with key opinion leaders in the field. The company operates in the medical device and biotech space.
- Who are Nectero Medical's investors?
- Nectero Medical's investors include Alumni Ventures, Aphelion Capital, Corewell Health Ventures, BioStar Capital, Norwest Venture Partners.
- How much funding has Nectero Medical raised?
- Nectero Medical has disclosed $51M raised across 2 of its 3 known rounds.
- Where is Nectero Medical headquartered?
- Nectero Medical is headquartered in Dover, US.